These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 9094648)

  • 1. Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals.
    Moog C; Fleury HJ; Pellegrin I; Kirn A; Aubertin AM
    J Virol; 1997 May; 71(5):3734-41. PubMed ID: 9094648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human immunodeficiency virus (HIV)-positive sera obtained shortly after seroconversion neutralize autologous HIV type 1 isolates on primary macrophages but not on lymphocytes.
    Ruppach H; Nara P; Raudonat I; Elanjikal Z; Rübsamen-Waigmann H; Dietrich U
    J Virol; 2000 Jun; 74(12):5403-11. PubMed ID: 10823844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autologous HIV-1 neutralizing antibodies: emergence of neutralization-resistant escape virus and subsequent development of escape virus neutralizing antibodies.
    Arendrup M; Nielsen C; Hansen JE; Pedersen C; Mathiesen L; Nielsen JO
    J Acquir Immune Defic Syndr (1988); 1992; 5(3):303-7. PubMed ID: 1740756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutralizing antibodies against sequential autologous human immunodeficiency virus type 1 isolates after seroconversion.
    Tsang ML; Evans LA; McQueen P; Hurren L; Byrne C; Penny R; Tindall B; Cooper DA
    J Infect Dis; 1994 Nov; 170(5):1141-7. PubMed ID: 7963706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutralization of primary human immunodeficiency virus type 1 isolates: a study of parameters implicated in neutralization in vitro.
    Moog C; Spenlehauer C; Fleury H; Heshmati F; Saragosti S; Letourneur F; Kirn A; Aubertin AM
    AIDS Res Hum Retroviruses; 1997 Jan; 13(1):19-27. PubMed ID: 8989423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera.
    Albert J; Abrahamsson B; Nagy K; Aurelius E; Gaines H; Nyström G; Fenyö EM
    AIDS; 1990 Feb; 4(2):107-12. PubMed ID: 2328092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutralizing antibody and perinatal transmission of human immunodeficiency virus type 1. New York City Perinatal HIV Transmission Collaborative Study Group.
    Hengel RL; Kennedy MS; Steketee RW; Thea DM; Abrams EJ; Lambert G; McDougal JS
    AIDS Res Hum Retroviruses; 1998 Apr; 14(6):475-81. PubMed ID: 9566549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa.
    Bures R; Morris L; Williamson C; Ramjee G; Deers M; Fiscus SA; Abdool-Karim S; Montefiori DC
    J Virol; 2002 Mar; 76(5):2233-44. PubMed ID: 11836401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid evolution of the neutralizing antibody response to HIV type 1 infection.
    Richman DD; Wrin T; Little SJ; Petropoulos CJ
    Proc Natl Acad Sci U S A; 2003 Apr; 100(7):4144-9. PubMed ID: 12644702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of sera from subjects infected with HIV-1 subtypes B and E in Thailand by antibody binding and neutralization.
    Louisirirotchanakul S; Beddows S; Cheingsong-Popov R; Shaffer N; Mastro TD; Auewarakul P; Likanonsakul S; Wasi C; Weber J
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Dec; 19(4):315-20. PubMed ID: 9833739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Broad cross-neutralizing activity in serum is associated with slow progression and low risk of transmission in primate lentivirus infections.
    Fenyö EM; Putkonen P
    Immunol Lett; 1996 Jun; 51(1-2):95-9. PubMed ID: 8811351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1.
    Moore JP; Cao Y; Ho DD; Koup RA
    J Virol; 1994 Aug; 68(8):5142-55. PubMed ID: 8035514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutralizing antibody responses against autologous and heterologous viruses in acute versus chronic human immunodeficiency virus (HIV) infection: evidence for a constraint on the ability of HIV to completely evade neutralizing antibody responses.
    Deeks SG; Schweighardt B; Wrin T; Galovich J; Hoh R; Sinclair E; Hunt P; McCune JM; Martin JN; Petropoulos CJ; Hecht FM
    J Virol; 2006 Jun; 80(12):6155-64. PubMed ID: 16731954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutralization of human immunodeficiency virus type 1 (HIV-1) mediated by parotid IgA of HIV-1-infected patients.
    Moja P; Tranchat C; Tchou I; Pozzetto B; Lucht F; Desgranges C; Genin C
    J Infect Dis; 2000 May; 181(5):1607-13. PubMed ID: 10823760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation between susceptibility of primary HIV-1 isolates to autologous and heterologous neutralizing antibodies. Hospital Evandro Chagas AIDS Clinical Research Group.
    Bongertz V; Costa CI; Santos VG; João Filho EC; Galvão-Castro B; Morgado MG
    AIDS; 1997 Jul; 11(8):969-75. PubMed ID: 9223730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of neutralizing and enhancing antibodies to human immunodeficiency virus type 1 primary isolates in plasma of individuals infected with env Genetic subtype B and E viruses in Thailand.
    Auewarakul P; Louisirirotchanakul S; Sutthent R; Taechowisan T; Kanoksinsombat C; Wasi C
    Viral Immunol; 1996; 9(3):175-85. PubMed ID: 8890476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isolate-specific neutralizing antibodies in patients with progressive HIV-1-related disease.
    Von Gegerfelt A; Albert J; Morfeldt-Månson L; Broliden K; Fenyö EM
    Virology; 1991 Nov; 185(1):162-8. PubMed ID: 1926772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A longitudinal assessment of autologous neutralizing antibodies in children perinatally infected with human immunodeficiency virus type 1.
    Geffin R; Hutto C; Andrew C; Scott GB
    Virology; 2003 Jun; 310(2):207-15. PubMed ID: 12781708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cross-neutralizing antibodies to HIV-1ANT70 and HIV-1IIIB in sera of African and Belgian HIV-1-infected individuals.
    Nkengasong JN; Peeters M; Ndumbe P; Janssens W; Willems B; Fransen K; Ngolle M; Piot P; van der Groen G
    AIDS; 1994 Aug; 8(8):1089-96. PubMed ID: 7986404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutralizing antibodies associated with viremia control in a subset of individuals after treatment of acute human immunodeficiency virus type 1 infection.
    Montefiori DC; Hill TS; Vo HT; Walker BD; Rosenberg ES
    J Virol; 2001 Nov; 75(21):10200-7. PubMed ID: 11581388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.